Danish researchers analysed data from over 77,000 people using anti-obesity drugs without diabetes. They found that 52 percent stopped taking their medications within one year. Eighteen percent quit within three months, 31 percent stopped by six months, and 42 percent abandoned treatment by nine months.
Younger, Poorer, and Male Patients Quit More
The study revealed that adults under 30 stopped 48 percent more often than those aged 45 to 59. Residents of low-income areas quit 14 percent more frequently than wealthier counterparts. Men showed higher dropout rates than women. Researchers noted that previous use of gastrointestinal or psychiatric medications might indicate unpleasant side effects such as nausea or vomiting, which contributed to early discontinuation.
GLP-1 Drugs Require Long-Term Use
Ozempic and Wegovy belong to the GLP-1 receptor agonist class, which suppresses appetite and promotes weight loss. Professor Reimar W. Thomsen emphasized that these medications only work when taken continuously. “Stopping the drug eliminates all appetite-control benefits,” he said.
Patients who stop these drugs often regain lost weight, prompting debate over whether people must use them for life.
Costs and Access Affect Adherence
High costs create barriers for many patients. In Denmark, a month’s supply of Ozempic costs up to €313 without diabetes coverage, compared with €120 in Germany. Researchers linked financial strain to increased dropout rates, particularly in low-income communities.
Supporting Patients Could Improve Health Outcomes
Thomsen stressed that interventions must focus on encouraging adherence to reduce health risks. Weight loss medications can lower risks of heart disease, cancer, and addiction.
“With more than half of European adults living with overweight or obesity, helping patients stay on treatment can improve long-term health and quality of life,” he said.
The findings will appear at the European Association for the Study of Diabetes annual meeting in Vienna. Researchers called for policies to enhance patient support and access to these life-changing medications.
